Introduction
Dengue fever, caused by exposure to the dengue virus (DENV), is a serious and growing public health problem worldwide, particularly amongst those residing in urban areas of tropical and subtropical countries 1 . In Brazil, where all four dengue serotypes (DENV-1-4) circulate, an increasing trend in the incidence of dengue has been observed, along with increases in the number of hospitalizations and deaths from the disease 2 . Severe dengue is a main cause of hospitalization and death among children in many Asian and Latin American countries 1, 3 .
There is a lack of consensus on pathogenesis models for severe dengue in infants. In the first six months of life, high levels of transplacentally transferred maternal anti-DENV antibodies appear to protect infants from symptomatic dengue 4 . However, a progressive decline in these antibodies after birth may increase the risk of developing severe dengue among infants aged 6-12 months 4, 5 . It has been postulated that an immunological window characterized by subneutralizing levels of transplacentally transferred maternal anti-DENV antibodies is involved in the development of severe dengue in infants 4, 5, 6 . This has been confirmed by studies conducted in Southeast Asia, where severe dengue in children in the first months of life often occurs in primary dengue virus infection 3, 5, 7 .
Prospective cohort studies have proved important in understanding the epidemiology and immunopathogenesis of dengue fever in pediatric populations 6, 8, 9, 10 . However, few studies to date have involved children aged less than four years and only one published study has included Latin American populations 11 . There is a need to better understand -e.g., via birth cohort studies -dengue incidence, the kinetics of transplacentally transferred maternally anti-DENV antibodies and their relationship to the duration of protection against dengue in children in the Brazilian context. Therefore, we set up a prospective birth cohort study in the city of Recife, a dengue hyperendemic area in northeastern Brazil, between March 2011 and May 2012. This paper describes the design, methods and the field implementation of this cohort study. We also present the serotype-specific epidemiological profile of the maternal-child pairs, the preliminary results of follow-up of acute febrile syndrome and the frequency of dengue infection in the first year of life.
Methods
The birth cohort was established at the Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) a publicly funded teaching hospital in the city of Recife. The parturient enrolment occurred in the maternity ward of IMIP, a large public maternity hospital in Northeast Brazil (around 5,000 deliveries per year).
Recife 13 . During the period in which this cohort study was conducted, DENV-4 and DENV-1 serotypes have predominated in the region (Health Department of Pernambuco, personal communication, 2012).
Parturients included in the study were clinically assessed as having low risk pregnancies, resident in Recife, and agreed to have their children followed up for at least one year.
Children were followed during their first 24 months of age between May 2011 and June 2014; which included the time period of parturient recruitment and follow-up of children. Neonates were randomly allocated into two groups and examined after birth as follows: (a) Group 1 -months 2, 6, 10 and 18; (b) Group 2 -months 4, 8, 12 and 24 ( Figure 1 ). The study also included the screening of febrile syndromes during follow-up, in order to detect acute DENV infection.
In the child cohort, the main outcome was the detection of recent or current DENV infection by immunoglobulin M (IgM) capture ELISA (enzyme linked immunosorbent assay) and/or RT-PCR (reverse transcription polymerase chain reaction). Symptomatic dengue infection was defined as a positive result (IgM or RT-PCR) along with the report of current or previous acute febrile syndrome between birth and the first follow up (2-4 months); in the second (4-8 months) Figure 1 Flowchart of participants in the dengue birth cohort study.
and third (8-12 months) follow up evaluations. Asymptomatic dengue infection was defined by the detection of anti-dengue IgM antibodies and no report of previous or current occurrence of acute febrile syndrome.
The sample size was calculated based on an assumed incidence rate of 0.05, with a margin of error (two-tailed) of 0.05, yielding a sample size of 307 14 . To account for up to 25% losses to follow-up, the target number of pregnant women to be recruited was 375. Table 1 shows the measurements obtained during cohort enrolment, follow-up and evaluation of acute febrile events between scheduled visits during follow-up. In addition, it shows the laboratory tests performed at each phase of the study. The parturients were contacted at the time of hospital admission in order to check for the eligibility. They were informed about the study objectives, invited to participate and asked to read and sign a consent form. Interviews were conducted by trained nurses using a standardized questionnaire. Maternal blood samples (10mL) were collected after the enrollment interview to confirm current and previous dengue infection. Following delivery, a 10mL blood cord sample was obtained to assess current dengue infection as well as maternally transferred total and specific anti-DENV antibodies to the neonates. We previously reported the high seroprevalence of anti-dengue IgG antibodies among parturients enrolled in this cohort 15 .
The clinical evaluations were carried out at IMIP by two experienced pediatricians who recorded clinical data and anthropometric measures of the child in standardized questionnaires.
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Phase Measurements
Baseline ( After maternity discharge, a member of the research team contacted parents or guardians via telephone to schedule the follow-up evaluations of their children. They were also asked to contact the research team if the child had fever for more than 24 hours to provide medical care and investigate whether the acute febrile was related to dengue infection. A suspected dengue case was defined as the presence of fever and at least two more of the following symptoms: drowsiness, refusal of intake food and fluids, vomiting, diarrhea or loose stools, according to the Brazilian Ministry of Health 16 . In addition, children with fever without localizing signs and symptoms (example, otitis, pneumonia and others infections) were also considered as likely dengue cases and screened for dengue infection. Therefore, both groups (suspected dengue cases and fever without localizing signs and symptoms) had blood samples (2mL) taken to assess acute dengue infection through DENV IgM and RT-PCR. The guardians were asked to return to the clinic after 48 to 72 hours for another clinical evaluation by the pediatrician. They were also instructed to contact the research team if the child's clinical status worsened.
A venous blood sample (2mL) was obtained by an experienced phlebotomist 15 minutes after topical application of anesthetic (lidocaine gel) and directly collected into 5mL Vacutainer tubes. Serum samples were separated and stored into cryovials at -80ºC. All blood samples collected during the cohort enrollment (maternalchild pairs) and child follow-up are being tested for anti-dengue IgG via indirect Enzyme-Linked Immunosorbent Assay-ELISA (Panbio, Brisbane, Australia) and anti-dengue IgM via capture ELISA (PanBio and Focus Diagnostic, Cypress, USA). Dengue cases tracked in febrile infants were laboratory-confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR) and IgM-ELISA. RT-PCR was performed according to a standardized protocol described elsewhere 17 . Viral RNA was extracted from serum samples using QIAquick PCR purification kits (Qiagen, Valencia, USA).
Serotype-specific anti-DENV antibodies are being assessed by a plaque reduction neutralization test (PRNT) performed following a modified protocol from Morens et al. 18, 19 . This PRNT assay has been carried out using virus strains isolated from dengue cases diagnosed in the study setting (Pernambuco state). DENV-1 (PE/97-42735), DENV-2 (PE/95-3808), DENV-3 (PE/02-95016) and DENV-4 (PE/0081) were provided by the Public Health Laboratory of Pernambuco state (LACEN-PE). All laboratory assays and serological tests are being performed at the Virology Laboratory (LAVITE) at the Aggeu Magalhães Research Center, Oswaldo Cruz Foundation (CPqAM/ Fiocruz) in Recife, and in collaboration with the Center for Vaccine Research at the University of Pittsburgh (Pittsburgh, USA).
The standardized questionnaires for both parturients and children were entered into a secure electronic web-based platform (http://www. cpqam.fiocruz.br/questdengue/). Data entry has been performed in parallel with data collection (completed) and laboratory testing (ongoing). The database is held on an SQL Server 2000 (Microsoft Corp.) using GeneXus software, version 7.5 (http://www.genexus.com/); this server is maintained at CPqAM/Fiocruz. Stata version 12 (StataCorp LP, College Station, USA) is being used for data analysis.
The maternal and umbilical cord dengue serotype-specific antibodies titers will be estimated using non-linear regression and the values will be log-transformed. A subset of the children cohort will be randomly selected to assess the kinetics of transplacentally transferred maternal anti-DENV antibodies and antibody enhancement via flow cytometry.
The protocol was approved by Ethics Research Committee of CpqAM/Fiocruz (59/10; CAAE-0061.0.095.000-10) and the IMIP (n o 2744 Dec 26, 2010). Figure 1 illustrates the cohort enrollment; follow up, including the number of children seen at each scheduled examination. From 934 parturients that fulfilled the inclusion criteria, 417 women were recruited. Of the parturients recruited, two were transferred to another hospital yielding a total of 415 parturients enrolled.
Results
Of the 415 children whose mothers were recruited into the cohort, 354 (85.3%) were examined in at least one of the four scheduled clinical assessments, resulting in 14.7% of individuals lost to follow-up (overall attrition rate). Most losses to follow-up were due to refusal, followed by difficulties in tracing cohort participants because of incorrect address provision and/or a change in place of residence. Table 2 shows the comparative analysis of the baseline characteristics of children who were followed and not followed in this dengue birth cohort; there were no statistically significant differences in the characteristics between these groups. Table 3 presents the main clinical and laboratory characteristics of the cohort. The determination of the DENV serotype-specific profile of the parturients showed that monotypic infection by DENV-3 (52%) predominated, followed by dual infection by DENV-3 and DENV-4 (29.3%).
Dengue infection (dengue IgM capture ELISA and/or RT-PCR) varied from 7.3% to 10.7% in the second and third follow-up. The proportion of dengue infections that were symptomatic was 37%, therefore the ratio of symptomatic to asymptomatic dengue infection in one-year follow up was 1:1.7. These preliminary results were estimated by anti-dengue IgM-ELISA (Focus Diagnostic, Cypress, USA).
Regarding acute febrile surveillance, 56 children were registered as a suspected dengue case or fever of unknown origin and 15 (26.7%) were virologically-confirmed by RT-PCR. Of note, we identified children infected with DENV-1 (n = 5), DENV-2 (n = 2), DENV-3 (n = 2) and DENV-4 (n = 6) by RT-PCR in the first year of the cohort. None of the infected children have evolved to severe dengue.
Discussion
Our preliminary results point out an overall rate of 10% new dengue infections (Ig M-ELISA or RT-PCR) during the first year of follow-up in this birth cohort assembled in the Northeast of Brazil, suggesting a high exposure of DENV virus in early life. The ratio of symptomatic to asymptomatic dengue infection of 1:1.7 found in this study, reinforces the knowledge of a higher frequency of unapparent infection compared with symptomatic infection detected by active surveillance 20 . During the child follow up, approximately 25% of clinically suspected dengue cases were virologically-confirmed. Of note, all serotypes (DENV-1 to DENV-4) were detected pointing out the simultaneous co-circulation of the different serotypes that is compatible with hyperendemicity in the study area 21 .
Half of the studied parturients had monotypic infection by DENV-3 and around 30% had dual infection by DENV-3 and DENV-4. This immune Cad. Saúde Pública, Rio de Janeiro, 32(1):e00095815, jan, 2016 Table 2 Comparison of maternal and child characteristics at baseline stratified by children followed and those not followed in the birth cohort study. 2, 17 . This maternal anti-dengue immune profile seems to be different from studies conducted in pregnant women in Asian countries where the majority of pregnant women were immune against two or more DENV serotypes 5, 8, 9 . In these Asian countries, unlike Brazil 2 , a high proportion of dengue cases in infants progress to severe dengue forms 3, 21 . The difference in the maternal anti-dengue immune profile could be attributed to the diverse Brazilian epidemiological scenario. In our setting, a previous modeling study showed that dengue is hyperendemic and that the accumulation of multitypic immunity in adults could lead to a possible shift of dengue hemorrhagic fever to children in the future 12 .
We present in the current paper the preliminary results of the first birth cohort study conducted to investigate the incidence of pediatric dengue infection in a large urban area in the Northeast of Brazil. Few such cohort studies have been published in Latin America 22, 23 . This cohort will allow an in-depth analysis of the Table 3 Maternal and child clinical and laboratorial characteristics in the Brazilian dengue birth cohort study (N = 354). immunology and dynamics of maternally-transferred antidengue antibodies to be assessed in further studies. Data on the decay of maternally-transferred dengue antibodies during early life, measured in short time intervals (every two months) are crucial for assessing the rate of loss cross-immunity and dengue incidence during the first year of life. On the other hand, maintaining high compliance rates in order to ensure the internal validity of the results is one of the main challenges in conducting cohort studies (mainly those involving clinicinvasive visits) 24 . To minimize a potentially high attrition rate due to serial clinical investigations and blood sample collections, the cohort was divided into two groups with different follow-up schedules that captured clinical data and blood samples every two months during the first year of life and every six months during the second. This approach allowed for sequential data collection on a large number of age bands, i.e., every two months in the first year and at two different points (months 18 and 24) in the second year. In this regard, a 15% rate of attrition obtained in our study is considered acceptable in epidemiological cohorts 25 . In addition, the comparative analysis between the baseline characteristics of the children followed and those not followed showed no significant differences between these groups, which reduces the chance of selection bias.
Characteristics
Since the majority of women enrolled in this hospital-based study are from economically-deprived areas, it is possible that the incidence of dengue infection in the current study might be overestimated if extrapolated to the entire city. Another potential concern related to external validity is that the study population was a sample of parturients and neonates who were recruited at a large public maternity hospital; therefore, some data may not be representative of the general population in Recife and its surroundings or other regions with diverse dengue epidemiological patterns.
Some limitations related to diagnostic and laboratory methods also need to be considered. For instance, IgM through Capture ELISA methods have a high likelihood of producing falsepositive results, leading to difficulty in accurately measuring the incidence rate based on the detection of specific antibodies 26, 27 . In addition, information on the accuracy of these tests is lacking, as well as about the duration over which IgM specific antibodies can be detected in neonates and infants. To overcome these limitations, we used those assays with the greatest accuracy in terms of sensitivity and specificity 27 . However, these commercial IgM-based assays produced discrepant results when tested on cord samples at baseline 15 . It is generally agreed that IgM wanes to undetectable levels between two to six months after the onset of infection, so we expected to be able to capture most of the primary infections occurring during the observation period 28, 29 . Because IgM antibody response to DENV is lower in secondary than primary infections 29,30 , we may not be able to capture some secondary infections among the infants. Still, considering the short time of exposure in this birth cohort when compared to the adult population, secondary infection is likely to be a rare event in this age group. Given the above and as proposed by Kassanjee et al. 31 , it is necessary to consider both the mean duration of the presence of detectable levels of IgM as well as the expected rates of false IgM positives when calculating incidence in this study. Issues related to the severity of dengue disease were out of the scope of this cohort study considering the low frequency of this event among children in our setting.
Our cohort design will bring attention to the serotype-specific force of infection in the early years of life in Brazil. Of note, this study has shown the feasibility of establishing birth cohorts in our region, as well as some innovative methodological approaches employed to minimize loss to follow up in a birth cohort. Finally, the study also allowed establishing a biobank to investigate biological events (the transference of DENVspecific IgG isotypes, enhancement activity, and complement activation mediated by maternallyacquired antibodies). These issues are essential for a better understanding of the dynamic of maternal child immunity related to dengue infection in the Brazilian epidemiological context. We highlight the potential of birth cohorts with extended follow up to provide information on dengue incidence, and other viral infections in different epidemiological scenarios to complement the official surveillance. 
